Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $304.26 Average Target Price from Analysts
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty-five brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and twenty have given a buy recommendation to the […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty-five brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and twenty have given a buy recommendation to the […]
